Navigation Links
China Shenghuo Pharmaceutical Reports Financial Results for the First Quarter of 2011
Date:5/16/2011

KUNMING, China, May 16, 2011 /PRNewswire-Asia-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. (NYSE Alternext US: KUN) ("China Shenghuo" or the "Company"), today reported unaudited financial results for the first quarter ended March 31, 2011.

First Quarter 2011 Highlights

  • Total revenue increased to $9.4 million for the first quarter of 2011, representing 19% year-over-year growth.
  • Net cash provided by operating activities was approximately $2.6 million, an increase of approximately $0.6 million, from approximately $2.0 million for the first quarter ended March 31, 2010.
  • Net income attributable to stockholders increased to $99,373, as compared to $2,355 for the first quarter ended March 31, 2010.

  • First Quarter 2011 ResultsSales: Sales for the three months ended March 31, 2011 was approximately $9.4 million, an increase of approximately $1.5 million, or 19 %, from approximately $7.9 million for the three months ended March 31, 2010. The increase in sales was primarily due to the Company's main product Xuesaitong's sales increasing in Tianjin City and Yunnan Province as Xuesaitong was listed on the Provincial Insurance Catalog list of Tianjin City since the second quarter in 2010 and the Company strengthened sales promotion in Yunnan Province.

    Cost of goods sold: Our cost of goods sold for the three months ended March 31, 2011 was approximately $3.8 million, an increase of $1.7 million, or 83%, from approximately $2.1 million for the three months ended March 31, 2010. The increase in cost of goods sold was primarily due to the increase of purchase price of Sanqi which is the main raw material of our main product Xuesaitong. In addition, the Zhonghuang Hotel began trial operation since January 2011 which has contributed $0.4 million to the increase of cost of goods sold.

    Gross profit: Our gross profit for the three months ended March 31, 2011 was approximately $5.6 million as compared with approximately $5.8 million for the three months ended March 31, 2010, a decrease of $0.2 million, or 3%. Gross profit as a percentage of revenues was approximately 59.7% for the three months ended March 31, 2011, a decrease of 14.0% from 73.7% for the three months ended March 31, 2010. The decrease in gross profit percentage was primarily due to the increase of cost of goods sold set forth above.

    Selling expense: Selling expenses were approximately $4.1 million for the three months ended March 31, 2011, a decrease of $1.0 million, or 19%, from approximately $5.1 million for the three months ended March 31, 2010. The primary reason for the decrease in selling expenses was due to decrease of commission to sales representative as a result of change of sales commission policy which took effect since the second quarter of 2010.

    General and administrative expense: General and administrative expenses were approximately $1.0 million for the three months ended March 31, 2011, an increase of $0.3 million, or 51%, from approximately $0.7 million for the three months ended March 31, 2010. The increase was primarily due to the increase of the management's traveling expenses for expanding our sales channel. In addition, Zhonghuang Hotel began trial operation since January 2011 which has contributed $78,733 to the increase of general and administrative expense.

    Research and development expense: Research and development expense for the three months ended March 31, 2011 was $121,725, as compared to $80,851 for the period ended March 31, 2010, an increase of $40,874. The increase was primarily due to the increase in the expenditures for outside experts for the Sh1002's registration to FDA since late 2009.

    Other expenses: Other expenses were $306,883 for the three months ended March 31, 2011, which consisted of interest expense and non-operating expense, off set by subsidy income, interest income and non-operating income, an increase of $263,879, or 614%, from $43,004 for the three months ended March 31, 2010. The increase was mainly due to less subsidy income from provincial government as compared to the same period in 2010.

    Income tax (expense) benefit: Income tax expense was $14,980 for the three months ended March 31, 2011 as compared to income tax benefit of $29,984 for the three months ended March 31, 2010.  The tax expense was mainly for tax accrued for the profit of the Company.

    Net income attributable to stockholders: Net income increased to $99,373 for the three months ended March 31, 2011 as compared to $2,355 for the three months ended March 31, 2010. Offset by the increase in raw material price and the expenses related to the trial operation of Shenghuo Plaza, the increase in net income was primarily due to decrease of selling expenses as a result of decrease of sales commission to sales representatives.

    About China ShenghuoFounded in 1995, China Shenghuo is primarily engaged in the research, development, manufacture, and marketing of Sanchi-based medicinal and pharmaceutical, nutritional supplement and cosmetic products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd., it owns thirty SFDA (State Food and Drug Administration) approved medicines, including the flagship product Xuesaitong Soft Capsules, which is currently being listed in the 2010 Provincial Insurance Catalogue of sixteen provinces and remains in the 2009 Provincial Insurance Catalogue of three provinces around China. At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Singapore, Japan, Malaysia, and Thailand and to European countries such as the United Kingdom, Tajikistan, Russia and Kyrgyzstan.

    With the substantial completion of Shenghuo Plaza at the end of 2010, China Shenghuo entered into a new business - the hotel and hospitality business.  Two floors of Shenghuo Plaza are designed to be utilized as 12 Ways Chinese Herbal Beauty Demonstration Center.  The balance of Shenghuo Plaza is used as a business hotel - Zhonghuang Hotel, restaurant and banquet facilities and an entertainment venue.

    China Shenghuo is also expanding into the businesses of wellness tourism.  For more information, please visit http://www.shenghuo.com.cn.

    Safe Harbor StatementThis press release may contain certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and the actual results and future events could differ materially from management's current expectations. Such factors include, but are not limited to, risks of litigation and governmental or other regulatory proceedings arising out of or related to any of the matters described in recent press releases, including arising out of the restatement of the Company's financial statements; the Company's ability to refinance or repay loans received; the Company's uncertain business condition; the Company's continuing ability to satisfy any requirements which may be prescribed by the Exchange for continued listing on the Exchange; risks arising from potential weaknesses or deficiencies in the Company's internal controls over financial reporting; the Company's reliance on one supplier for Sanchi; the possible effect of adverse publicity on the Company's business, including possible contract cancellation; the Company's ability to develop and market new products; the Company's ability to establish and maintain a strong brand; the Company's continued ability to obtain and maintain all certificates, permits and licenses required to open and operate retail specialty counters to offer its cosmetic products and conduct business in China; protection of the Company's intellectual property rights; market acceptance of the Company's products; changes in the laws of the People's Republic of China that affect the Company's operations; cost to the Company of complying with current and future governmental regulations; the impact of any changes in governmental regulations on the Company's operations; general economic conditions; and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Company Contact:China Shenghuo Pharmaceutical Holdings, Inc.Ms. Hongling FeiDirector of Securities Department+86-871-7282698Investor Relations Contact:The Trout GroupMark Xu+86-15821996861CHINA SHENGHUO PHARMACEUTICAL HOLDINGS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(Amounts in USD)March31,December 31,20112010(Unaudited)Assets:Current assets:   Cash and cash equivalents

    $

    1,409,304$

    1,669,387   Accounts and notes receivable, net13,721,29911,531,027   Other receivables, net4,025,2844,111,315   Advances to suppliers567,477580,168   Inventories2,759,7592,599,351   Due from related parties279,077190,614   Current deferred tax assets1,003,443833,568   Other current assets143,964208,111Total current assets23,909,60721,723,541   Property, plant and equipment, net 21,342,26321,069,139   Other non-current assets2,497,0632,554,193$

    47,748,933$

    45,346,873CHINA SHENGHUO PHARMACEUTICAL HOLDINGS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS (CONT'D)(Amounts in USD)March 31,December 31,20112010Liabilities and equity:(Unaudited)Current liabilities:   Accounts payable

    $

    8,218,246

    $

    8,964,404   Other payables and accrued expenses11,148,8349,699,857   Sales representative deposits4,811,5694,936,429   Due to related parties-79,864   Short-term borrowings4,722,3135,289,178   Advances from customers2,747,5171,158,649   Taxes payables and other current liabilities1,540,686881,506   Current portion of long-term borrowings6,097,4686,039,833Total current liabilities39,286,63337,049,720Long-term borrowings6,310,8796,251,22745,597,51243,300,947Commitments and contingenciesEquity:   Common stock, $0.0001 par value, 100,000,000 shares authorized and 19,679,400 shares issued and outstanding, both periods1,9681,968   Additional paid-in capital6,193,9276,193,927   Appropriated retained earnings147,023147,023   Accumulated deficit(5,841,066)(5,940,439)   Accumulated other comprehensive income1,661,0611,638,109Total stockholder's equity2,162,9132,040,588Non-controlling interest(11,492)5,338Total equity2,151,4212,045,926$

    47,748,933$

    45,346,873CHINA SHENGHUO PHARMACEUTICAL HOLDINGS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF INCOMEAND COMPREHENSIVE INCOME (UNAUDITED)(Amounts in USD, except shares)Three months ended March 31,20112010(Unaudited)(Unaudited)Sales

    $

    9,441,626

    $

    7,907,002Cost of goods sold3,805,6922,076,353Gross profit5,635,9345,830,649Operating expenses:   Selling expenses4,076,4305,051,714   General and administrative expenses1,030,215684,259   Research and development expense121,72580,8515,228,3705,816,824Income from operations407,56413,825Other income (expenses):   Subsidy income7,598153,598   Interest and other income (expense)(314,481)(196,602)(306,883)(43,004)Income (loss) before income tax expenses100,681(29,179)Income tax (expense) benefit (14,980)29,984Net income85,701805Less: net loss attributable to non-controlling

    interests(13,672)(1,550)Net income attributable to stockholders$99,373$2,355Comprehensive income:Net income 85,701805   Foreign currency translation adjustment19,794331Comprehensive income$105,495$1,136Less: comprehensive loss attributable to  

    non-controlling interests(16,830)(2,187)Comprehensive income attributable tostockholders122,3253,323Basic and diluted earnings per share$

    0.01$

    0.00Weighted-average number of shares outstanding-basic and diluted  - basic and diluted19,679,40019,679,400CHINA SHENGHUO PHARMACEUTICAL HOLDINGS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)(Amounts in USD)Three months ended March 31,20112010(Unaudited)(Unaudited)Net cash provided by operating activities$

    2,609,836$2,022,198Cash flows from investing activities:Purchase of long-lived assets(2,290,979)(3,205,176)Proceeds from disposal of property169131,913Net cash used in investing activities(2,290,810)(3,073,263)Cash flows from financing activities:Proceeds from borrowings3,292,3269,563,858Payments on borrowings(3,886,067)(9,636,020)Net cash used in financing activities (593,741)(72,162)Effect of foreign currency fluctuation on cash and cash equivalents14,632492Net decrease in cash and cash equivalents(260,083)(1,122,735)Cash and cash equivalents at beginning of period1,669,3871,986,540Cash and cash equivalents at end of period$

    1,409,304$

    863,805Supplemental informationCash paid for interest

    $

    332,323

    $

    261,726Cash paid for income taxes

    $

    -

    $

    -
    '/>"/>

    SOURCE China Shenghuo Pharmaceutical Holdings, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. China Pharma Holdings, Inc. to Present at the Eighth Annual Piper Jaffray China Growth Conference in New York on May 17, 2011
    2. Winner Medical to Present at Oppenheimer 5th Annual China Dragon Conference
    3. Naviscan Announces Partnership With Chindex Medical Limited for Mainland China, Hong Kong and Macau
    4. China New Borun Announces First Quarter 2011 Financial Results
    5. China Pharma Holdings, Inc. Reports First Quarter 2011 Financial Results
    6. Reportlinker Adds Orthopedic Devices Market in the Emerging Countries (China, India, Brazil) - Presenting New Avenues for Growth and Profitability
    7. Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China
    8. China Medical Technologies to Present at Jefferies 2011 Global Healthcare Conference on June 7, 2011
    9. ThermoGenesis Reports Third Quarter Fiscal 2011 Results; Major Progress Achieved in China & India
    10. China Sky One Medical Announces Conference Call to Discuss First Quarter 2011 Results
    11. ICSE China to Offer Inaugural Conference Programme in 2011
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/25/2016)... 25, 2016 MedDay, a biotechnology company ... an oral presentation entitled "High doses of biotin in progressive ... be given by Professor Ayman Tourbah , Principal Investigator ... the European Academy of Neurology (EAN) in Copenhagen, ... 3" will take place on Sunday, 29 May 2016 from ...
    (Date:5/24/2016)... 24, 2016 Cirujanos holandeses han ... a los médicos a compartir sus mejores prácticas por ... mundial. Profesionales médicos de Europa, África, Asia ... a la aplicación, que combina la transmisión en vivo ... seguro. Educación   "Imagine un médico ...
    (Date:5/24/2016)... 2016 ARANZ Medical  Ltd a ... sector, has been named the Coretex Hi-Tech Emerging Company of ... Dr Bruce Davey , CEO of ARANZ Medical ... really good to be recognised for the work we are ... used in 35 countries around the world from Sub-Saharan Africa ...
    Breaking Medicine Technology:
    (Date:5/28/2016)... ... 2016 , ... May 26, 2016- In search of the K. Warriors, Shaolin ... of “K Warriors” on June 4, 2016 at Ashbury Hotel and Suites 600 West ... and hosted by Shaolin Institute and sanctioned by KSF (Kungfu Sanda Federation), This is ...
    (Date:5/27/2016)... ... May 27, 2016 , ... More than a third of ... not surprising that bariatric surgery has received increased attention in recent years, as an ... when it comes to weight loss, most people are familiar with the basic requirements ...
    (Date:5/27/2016)... Gilsum, New Hampshire (PRWEB) , ... May 27, 2016 , ... ... natural skin care products, announced today that it has been recognized as one of ... men entering parenthood. Badger was named as one of nine small businesses providing progressive ...
    (Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... This campaign ... a stroke, which we as a society can control and change. , As nearly ... nearly every 40 seconds within the United States. Plus, with an estimated 129,000 of ...
    (Date:5/27/2016)... ... ... Beleza Medspa has initiated a new program to assist active duty ... that Coolsculpting is being used for for more than just cosmetic purposes. ... prescribed body-fat standard, measured by the circumference-based tape method. The tape-test is used ...
    Breaking Medicine News(10 mins):